JP2018535404A5 - - Google Patents

Download PDF

Info

Publication number
JP2018535404A5
JP2018535404A5 JP2018516740A JP2018516740A JP2018535404A5 JP 2018535404 A5 JP2018535404 A5 JP 2018535404A5 JP 2018516740 A JP2018516740 A JP 2018516740A JP 2018516740 A JP2018516740 A JP 2018516740A JP 2018535404 A5 JP2018535404 A5 JP 2018535404A5
Authority
JP
Japan
Prior art keywords
hgdf
cancer
detection kit
level
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018516740A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535404A (ja
JP6858181B2 (ja
Filing date
Publication date
Priority claimed from GBGB1517527.6A external-priority patent/GB201517527D0/en
Priority claimed from GBGB1607800.8A external-priority patent/GB201607800D0/en
Application filed filed Critical
Priority claimed from PCT/EP2016/073519 external-priority patent/WO2017055612A1/en
Publication of JP2018535404A publication Critical patent/JP2018535404A/ja
Publication of JP2018535404A5 publication Critical patent/JP2018535404A5/ja
Application granted granted Critical
Publication of JP6858181B2 publication Critical patent/JP6858181B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018516740A 2015-10-02 2016-09-30 免疫チェックポイントブロッカーを用いる治療の臨床アウトカムを予測するための診断マーカーとしてのgdf−15 Active JP6858181B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1517527.6 2015-10-02
GBGB1517527.6A GB201517527D0 (en) 2015-10-02 2015-10-02 GDF-15 as a diagnosis marker to predict the clinical outcome of a treatment with immune checkpoint blockers
GB1607800.8 2016-04-29
GBGB1607800.8A GB201607800D0 (en) 2016-04-29 2016-04-29 GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
PCT/EP2016/073519 WO2017055612A1 (en) 2015-10-02 2016-09-30 Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers

Publications (3)

Publication Number Publication Date
JP2018535404A JP2018535404A (ja) 2018-11-29
JP2018535404A5 true JP2018535404A5 (OSRAM) 2021-01-21
JP6858181B2 JP6858181B2 (ja) 2021-04-14

Family

ID=57123979

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018516740A Active JP6858181B2 (ja) 2015-10-02 2016-09-30 免疫チェックポイントブロッカーを用いる治療の臨床アウトカムを予測するための診断マーカーとしてのgdf−15

Country Status (10)

Country Link
US (2) US11262360B2 (OSRAM)
EP (2) EP4321866A3 (OSRAM)
JP (1) JP6858181B2 (OSRAM)
KR (1) KR102621034B1 (OSRAM)
AU (1) AU2016333538B2 (OSRAM)
CA (1) CA3000290C (OSRAM)
DK (1) DK3356827T3 (OSRAM)
ES (1) ES2968226T3 (OSRAM)
FI (1) FI3356827T3 (OSRAM)
WO (1) WO2017055612A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013322628B2 (en) * 2012-09-26 2017-03-02 Julius-Maximilians-Universitat Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15)
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
DK3356827T3 (da) 2015-10-02 2024-01-08 Univ Wuerzburg J Maximilians Gdf-15 som en diagnostisk markør til forudsigelse af det kliniske resultat af en behandling med immun-checkpoint-blokkere
CA3019847A1 (en) 2016-04-04 2017-10-12 University Of Florida Research Foundation, Incorporated Manipulation of eif3 to modulate repeat associated non-atg (ran) translation
BR112018072034A2 (pt) 2016-05-24 2019-02-12 Novo Nordisk A/S compostos mic-1 e usos dos mesmos
AU2018255293B2 (en) 2017-04-17 2024-03-07 University Of Florida Research Foundation, Incorporated Regulation of RAN translation by PKR and eIF2a-P pathways
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Mic-1化合物及其用途
AU2018338451A1 (en) 2017-09-25 2020-04-02 University Of Florida Research Foundation, Incorporated Immunoassays for detection of RAN proteins
CA3128973A1 (en) 2019-03-04 2020-09-10 Bhaskar Bhattacharyya Data compression and communication using machine learning
KR102164432B1 (ko) 2019-09-18 2020-10-13 한국과학기술원 Dna 메틸화 변이를 이용한 면역항암치료 반응성 예측방법
CA3154741A1 (en) 2019-09-20 2021-03-25 University Of Florida Research Foundation, Incorporated Detection of antibodies against ran proteins from serum and tissue lysates
KR102238912B1 (ko) 2020-05-27 2021-04-12 한국과학기술원 Dna 메틸화 변이 및 종양 변이 부담을 이용한 면역항암치료 반응성 예측방법
CN112162097B (zh) * 2020-07-24 2022-04-01 广州医科大学 Gdf1作为评估pd-1单抗治疗效果的生物标志物
KR20230107309A (ko) 2020-11-10 2023-07-14 카탈임 게엠베하 항-gdf15 항체 및 암 치료용 투여 용법
CN112698042A (zh) * 2020-12-17 2021-04-23 北京赛诺浦生物技术有限公司 检测人生长分化因子-15的荧光免疫层析试纸条及其制备方法和应用
CN113252905A (zh) * 2021-05-12 2021-08-13 北京赛诺浦生物技术有限公司 人生长分化因子-15磁微粒化学发光检测试剂盒及其应用
CN113702647B (zh) * 2021-08-31 2024-03-15 普十生物科技(北京)有限公司 人生长分化因子15即时检测试剂盒、其制备方法及其应用
KR20230046264A (ko) 2021-09-29 2023-04-05 (주)펜타메딕스 Line-1의 dna 메틸화 변이를 이용한 면역항암치료 반응성 예측방법
CN115831306A (zh) * 2023-02-23 2023-03-21 北京康博众联电子科技有限公司 一种数据分析装置、方法及计算机存储介质
CN116462757A (zh) * 2023-03-24 2023-07-21 科兴生物制药股份有限公司 Gdf15的单域抗体及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6455677B1 (en) 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
ES2275513T3 (es) 1999-05-17 2007-06-16 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh Propiedades neuroprotectoras de gdf-15, un miembro de la superfamilia de tgf-beta.
WO2002020759A2 (en) 2000-09-08 2002-03-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
AU2005205533B2 (en) 2004-01-07 2012-03-22 Novartis Vaccines And Diagnostics, Inc. M-CSF-specific monoclonal antibody and uses thereof
US8192735B2 (en) 2004-04-13 2012-06-05 St Vincent's Hospital Sydney Limited Method for modulating appetite
WO2007067500A2 (en) 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors
CN101854947A (zh) 2007-08-16 2010-10-06 圣文森特医院悉尼有限公司 用于调节巨噬细胞抑制因子(mic-1)活性的药剂和方法
WO2009046495A1 (en) 2007-10-09 2009-04-16 St Vincent's Hospital Sydney Limited A method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1
WO2009150255A2 (en) * 2008-06-13 2009-12-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Markers for predicting response and survival in anti-egfr treated patients
BRPI0919531A2 (pt) 2008-09-29 2015-12-08 Roche Glycart Ag anticorpos contra il17 humana e usos dos mesmos
EP2209003A1 (en) * 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Means and methods for differentiating between fibrosis and cirrhosis
US7736861B1 (en) * 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
US20120309697A1 (en) 2009-10-28 2012-12-06 Samuel Norbert Breit Methods of diagnosing and prognosing colonic polyps
US9212221B2 (en) 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
MX355060B (es) 2010-11-17 2018-04-03 Chugai Pharmaceutical Co Ltd Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea.
ES2704038T3 (es) * 2011-05-24 2019-03-13 Zyngenia Inc Complejos multiespecíficos multivalentes y monovalentes y sus usos
WO2013012648A1 (en) 2011-07-15 2013-01-24 Emory University Gdf15 in diagnostic and therapeutic applications
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
EP2565262A1 (en) 2011-08-31 2013-03-06 VTU Holding GmbH Protein expression
BR112014018575A2 (pt) 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
AU2013322628B2 (en) 2012-09-26 2017-03-02 Julius-Maximilians-Universitat Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15)
CN105073133B (zh) 2012-12-21 2021-04-20 Aveo制药公司 抗gdf15抗体
CA2906523A1 (en) * 2013-03-15 2014-09-25 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
JP2015078138A (ja) 2013-10-15 2015-04-23 株式会社ニックス 小動物防除性樹脂組成物
AU2015206603B9 (en) * 2014-01-14 2019-07-18 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
EP2899544B1 (en) * 2014-01-28 2018-12-26 Roche Diagnostics GmbH Biomarkers for risk assessment and treatment monitoring in heart failure patients who receive B-type natriuretic peptide guided therapy
SI3134123T1 (sl) 2014-02-21 2021-08-31 Nektar Therapeutics (India) Pvt. Ltd. IL-2Rbeta-selektivni agonisti v kombinaciji s protitelesom proti- CTLA-4 ali protitelesom proti-PD-1
DK3122775T3 (da) 2014-03-26 2020-02-03 Univ Wuerzburg J Maximilians Monoklonale antistoffer til vækst- og differentieringsfaktor 15 (gdf-15), og anvendelser deraf til behandling af cancer kakeksi og cancer
EP3851122A1 (en) 2014-09-25 2021-07-21 Aveo Pharmaceuticals Inc. Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
DK3356827T3 (da) 2015-10-02 2024-01-08 Univ Wuerzburg J Maximilians Gdf-15 som en diagnostisk markør til forudsigelse af det kliniske resultat af en behandling med immun-checkpoint-blokkere
PT3355919T (pt) 2015-10-02 2023-01-06 Univ Wuerzburg J Maximilians Terapia de combinação utilizando inibidores do fator de crescimento e diferenciação 15 (gdf-15) humano e bloqueadores de pontos de controlo imunitários
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
EP3841121A2 (en) 2018-08-20 2021-06-30 Pfizer Inc. Anti-gdf15 antibodies, compositions and methods of use

Similar Documents

Publication Publication Date Title
JP2018535404A5 (OSRAM)
FI3356827T3 (fi) GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi
Sharma et al. Ultrasensitive direct impedimetric immunosensor for detection of serum HER2
JP2015533788A5 (OSRAM)
Altintas et al. Surface plasmon resonance based immunosensor for the detection of the cancer biomarker carcinoembryonic antigen
JP2017518366A5 (OSRAM)
ES2641294T3 (es) Nuevo anticuerpo para el diagnóstico y/o el pronóstico del cáncer
JP2014524744A5 (OSRAM)
RU2008139098A (ru) Способы диагностики рака поджелудочной железы с применением белка reg4
NZ716369A (en) Anti-ox40 antibodies and methods of using the same
EP3349011B1 (en) Liver cancer test method
Qu et al. A rapid and highly sensitive portable chemiluminescent immunosensor of carcinoembryonic antigen based on immunomagnetic separation in human serum
RU2015103228A (ru) Антитела против тау
JP2015502547A5 (OSRAM)
JP2011530514A5 (OSRAM)
RU2017119009A (ru) Анализы для обнаружения субпопуляций иммунных т-клеток и способы их применения
WO2013132347A3 (en) Improved elisa immunoassay for calprotectin
JP2018520668A5 (OSRAM)
JP2020510409A5 (OSRAM)
RU2016116773A (ru) Способ выявления опухоли поджелудочной железы, антитела и набор для выявления опухоли поджелудочной железы
Yan et al. A novel rapid quantitative method reveals stathmin‐1 as a promising marker for esophageal squamous cell carcinoma
RU2014128510A (ru) Способ определения свободного связывающего партнера мультиспецифичного связующего
JP2016516008A5 (OSRAM)
RU2008103608A (ru) Выявление антигена-мишени вне зависимости от присутствия или отсутствия соответствующего терапевтического антитела
JP2008545145A5 (OSRAM)